Enhancement of normal polymorphonuclear cells respiratory burst in ascitic fluid by fibronectin. Comparison between cirrhotic and malignant ascitic fluids.
The chemiluminescence (CL) response of normal peripheral blood polymorphonuclear cells (PMN) in ascitic fluids (cirrhotic = 32; malignant = 17) was studied independently of the ascitic fluid complement activity. CL response and fibronectin levels were higher in malignant ascitic fluid than in cirrhotic ascitic fluid (p less than 0.001). Addition of pure fibronectin or malignant ascitic fluids to cirrhotic ascitic fluids increased the CL response of normal PMN. These findings suggest that the susceptibility of cirrhotic patients to spontaneous bacterial peritonitis (SBP) is a multifactorial defect involving factors distinct from low C3 levels. Fibronectin is an important factor in the promotion of the respiratory burst of normal PMN stimulated by opsonized zymosan or PMA in ascitic fluid. Our results suggest that low levels of ascitic fluid fibronectin could partly explain the high susceptibility of cirrhotic patients to spontaneous bacterial peritonitis.
Lebrun
L
L
INSERM U 131, Hôpital A. Béclère, Clamart, France.
Pelletier
G
G
Briantais
M J
MJ
Brivet
M
M
Khellaf
A
A
Galanaud
P
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001202:Ascitic Fluid / Q000737:chemistry / Q000166:cytology* / Q000378:metabolism; D001424:Bacterial Infections; D004198:Disease Susceptibility; D004305:Dose-Response Relationship, Drug; D005260:Female; D005353:Fibronectins / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008163:Luminescent Measurements; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism* / Q000502:physiology; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D010538:Peritonitis / Q000453:epidemiology / Q000209:etiology; D016897:Respiratory Burst / Q000187:drug effects* / Q000502:physiology; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
D005353:Fibronectins; D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate